Form 4: Anika Therapeutics Director Joseph Capper Granted 14,164 Restricted Stock Units

Anika Therapeutics, Inc. Director Joseph H. Capper was granted 14,164 restricted stock units (RSUs) on June 20, 2025, increasing his beneficial ownership to 20,403 shares.

Summary

• Joseph H. Capper, a Director of Anika Therapeutics, Inc. (ANIK), acquired 14,164 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was June 20, 2025.
• Each RSU represents the contingent right to receive one share of the Company's common stock.
• The RSUs were acquired at a price of $0 per unit, which is typical for RSU grants as part of compensation.
• Following this transaction, Mr. Capper's direct beneficial ownership of Anika Therapeutics common stock increased to 20,403 shares.
• The RSUs are scheduled to vest in full on the earlier of the Company's 2026 annual meeting of stockholders or June 20, 2026.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive signal of alignment between management and shareholder interests, and a standard compensation practice. It's not a major financial event but indicates stability in governance.

Positives

• The grant of 14,164 Restricted Stock Units (RSUs) to Director Joseph H. Capper aligns his interests with long-term shareholder value.
• The increase in beneficial ownership to 20,403 shares demonstrates continued commitment from a key director.

Future Outlook

The 14,164 Restricted Stock Units granted to Director Joseph H. Capper are set to vest in full on the earlier of the Company's 2026 annual meeting of stockholders or June 20, 2026, indicating a future milestone for this compensation.

Industry Context

This filing is a routine disclosure of insider compensation, common across all publicly traded companies, reflecting standard practices for aligning director incentives with company performance. It does not provide broader industry trends.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) at a $0 price is a standard form of equity compensation for directors and executives across various industries, aligning their long-term interests with shareholder value.
• The vesting schedule, tied to a future annual meeting or a specific date, is a common mechanism to ensure retention and performance incentives, comparable to practices at companies like Stryker Corporation (SYK) or Zimmer Biomet Holdings (ZBH) in the medical technology sector, though specific grant sizes vary by company size and individual role.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's interests with long-term shareholder value, as the value of the RSUs is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: Reinforces compensation structure for directors.

Next Steps

• Vesting of the 14,164 Restricted Stock Units on the earlier of the 2026 annual meeting of stockholders or June 20, 2026.

Key Dates

Keywords

Anika Therapeutics, ANIK, Joseph H. Capper, Form 4, SEC Filing, Restricted Stock Units, RSU, Insider Trading, Director Compensation, Beneficial Ownership